Hepatocellular carcinoma
Conditions
Interventions
FOLFOX therapy group:Adjuvant therapy 8~12 cycles with FOLFOX
Sponsors
Cancer Center of SUN Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age 18~75 years; 2. ECOG PS score =1.5*10^9/L; (2) Hemoglobin >=90g/L; (3) Platelet count >=75*10^9/L; (4) Serum albumin >=35g/L; (5) Serum total bilirubin <=1.5*ULN (upper limit of normal); (6) Serum AST and ALT <2.5*ULN; (7) Serum creatinine <=1.5*ULN; (8) INR <=1.5; 9. Give signed informed consent before enrollment.
Exclusion criteria
Exclusion criteria: 1. Function impairment of vital organs (heart, lung, kidney, etc), serious infection or >grade 2 adverse events (CTCAE Version 3.0); 2. Histologically confirmed of positive resection margin (R1 resection); 3. Previous or current malignant tumor beyond HCC; 4. Allergy to any agent of the FOLFOX regimen; 5. History of organ transplantation; 6. Previously receiving other treatments for HCC; 7. Pregnant or breastfeeding women, and women of childbearing potential without adequate contraception; 8. Neurological or mental abnormalities that may affect cognitive assessment and inform consent; 9. Concomitant anti-tumor therapy or participating in other interventional clinical trials 10. Other psychological, family or social reason, which would affect compliance with the study protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Recurrence rate;Overall survival;Safety profile; | — |
Countries
China
Contacts
Public ContactGuo Rongping
Outcome results
None listed